Eli Lilly and Novartis are tenants at the San Diego campus behind KKR's $475 million deal.
KKR acquired the Campus Point Megacampus in San Diego for $475 million. Tenants include Eli Lilly, Novartis, and Bristol Myers Squibb. Alexandria Real Estate Equities, the seller, will use proceeds to optimize capital structure and support future investments. KKR and Alexandria are publicly traded (KKR, ARE).
How this was made
The 30-second read
Why it matters
The acquisition expands KKR's footprint in the life‑science real‑estate niche while providing ARE liquidity for redeployment.
Market read
The $475 million deal is material for both firms and signals continued interest in life‑science real‑estate assets.
What to watch
Long‑term lease terms and tenant credit quality could mitigate valuation concerns
Background
KKR and Alexandria Real Estate Equities disclosed the transaction via a Business Wire press release.
Ticker impact
KKR announced a $475 million acquisition of the Campus Point megacampus in San Diego.
potential upside as market prices in added cash‑flow from high‑quality tenants
Deal size is material and adds stable lease income, but valuation impact depends on financing terms.
Alexandria Real Estate Equities (ARE) is the seller of the Campus Point megacampus to KKR.
likely modest pressure as proceeds may be used for share buybacks or new investments
Transaction is a significant asset divestiture but does not immediately alter earnings guidance.
Market effects
adds exposure to life‑science real‑estate sector for KKR and frees capital for ARE
affects US REIT and private‑equity markets
moderate, given the involvement of multinational pharma tenants
Counterpoint
Deal may overprice the campus amid high cap‑rate environment, risking lower returns
Key entities
- CompanyKKR & Co. Inc.
Global investment firm acquiring the campus.
- CompanyAlexandria Real Estate Equities, Inc.
Seller of the Campus Point megacampus.
